TScan Therapeutics
TCRX
Market cap $279M

5.27 USD

+0.00

0.00%

Updated Oct 22, 10:41 AM EDT

1 day

0.00%

5 days

-5.72%

1 month

1.35%

3 months

-23.51%

6 months

-25.98%

Year to date

-7.71%

1 year

71.66%

5 years

-49.81%

About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 188

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

82% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 17

21% more funds holding

Funds holding: 66 [Q1] → 80 (+14) [Q2]

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

6.16% more ownership

Funds ownership: 79.15% [Q1] → 85.31% (+6.16%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

12% less capital invested

Capital invested by funds: $274M [Q1] → $242M (-$31.7M) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

90%

upside

Avg. target

$12

128%

upside

High target

$15

185%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Wedbush David Nierengarten 49% 1-year accuracy 25 / 51 met price target	90%upside $10	Outperform Reiterated	13 Aug 2024
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target	185%upside $15	Buy Reiterated	13 Aug 2024
Needham Gil Blum 42% 1-year accuracy 40 / 95 met price target	109%upside $11	Buy Reiterated	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

TScan Therapeutics to Participate in Upcoming Investor Conferences

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

TScan Therapeutics focuses on TCR-T therapies for cancer and autoimmune diseases, leveraging its ImmunoBank and proprietary ReceptorScan platform. TCRX's pipeline is in the early clinical stages, with multiple near-term catalysts, including promising regulatory designations and potential partnerships. The company's leading candidates, TSC-100 and TSC-101, target AML, MDS, and ALL, with FDA RMAT designation potentially expediting approval.

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Zacks Investment Research

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Updates to its Board of Directors

Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors

TScan Therapeutics Announces Updates to its Board of Directors

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 5, 2024 at 11:00 a.m. Eastern Time.

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

Zacks Investment Research

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.93 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™